CompletedNCT00845507
Exenatide for weight gain during olanzapine treatment
About this title
Read the official source — NCT00845507Medication studyAges 18–55United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- CincinnatiSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 54
- Sponsor
- University of Cincinnati
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00845507
- Official title
Show the full official title
A Double-Blind Placebo-Controlled Study of Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults With Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cincinnati
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Cincinnati, a university.
Did this study involve medication?
Yes. The study involved medication, including Exenatide and Placebo.
Who was this study for?
Listed age limits: 18 years to 55 years.
